Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03961009 · ClinicalTrials.gov registry record · Phase 3
Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients
A Phase 3 study, sponsored by Kedrion S.p.A..
- Completed
- Registry status
- Phase 3
- Development phase
- 47
- Enrollment target
NCT03961009 is a Phase 3 study that has completed, run by Kedrion S.p.A.. The registered enrollment target is 47 participants.
The verdict
NCT03961009, a Phase 3 study, has completed, sponsored by Kedrion S.p.A..
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study was to assess efficacy and safety of Kedrion Immunoglobulin 10% (KIg10) in participants with Primary Immunodeficiency (PID).
Interventions
- BIOLOGICAL Kedrion IVIG 10%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2019-04-30 |
| Est. Completion | 2020-12-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03961009
The ClinicalTrials.gov registry entry for NCT03961009 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kedrion S.p.A., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Kedrion IVIG 10% is the first listed.
NCT03961009 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03961009 about?
NCT03961009 is a clinical study titled "Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients". The purpose of this study was to assess efficacy and safety of Kedrion Immunoglobulin 10% (KIg10) in participants with Primary Immunodeficiency (PID).
What is the current status of trial NCT03961009?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 47 participants. The study started on 2019-04-30. Estimated completion is 2020-12-21.
What interventions are being tested in trial NCT03961009?
The interventions under investigation include: Kedrion IVIG 10% (BIOLOGICAL).
Who is sponsoring clinical trial NCT03961009?
This trial is sponsored by Kedrion S.p.A., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.